α-Synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons

Neuroscience

Volumn 104, Issue 3, 2001, Pages 901-912

  McLean, P J ^a   Kawamata, H ^a   Hyman, B T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Synuclein; Aggregation; Lewy body; Parkinson's disease; Synphilin 1

Indexed keywords

ACETYLLEUCYLLEUCYLNORLEUCINAL; ALPHA SYNUCLEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CELL PROTEIN; ENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; EPITOPE; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; LACTACYSTIN; MUTANT PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN SYNPHILIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN; CELL INCLUSION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; FAMILIAL DISEASE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEWY BODY; MOUSE; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; CARRIER PROTEINS; CEREBRAL CORTEX; CRYOPROTECTIVE AGENTS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DIMETHYL SULFOXIDE; FETUS; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; LEUPEPTINS; LUMINESCENT PROTEINS; MICE; MULTIENZYME COMPLEXES; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SYNUCLEINS; TUMOR CELLS, CULTURED;

EID: 0035859226     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(01)00113-0     Document Type: Article

References (23)

1. α-Synuclein and the Parkinson's disease-related mutant Ala53Thr-α-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells
2. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
3. Degradation of α-synuclein by the proteasome
4. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
5. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
6. Synthetic filaments assembled from C-terminally truncated α-synuclein
7. Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions
8. Mutant and wild-type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro
9. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease
10. Oxidative stess induces amyloid-like aggregate formation of NACP/α-synuclein in vitro
11. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly
12. Nigral and cortical lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical lewy body disease contain α-synuclein immunoreactivity
13. Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
14. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
15. Lewy bodies are ubiquitinated: A light and electron microscopic immunocytochemical study
16. Proteasome inhibitors: Valuable new tools for cell biologists
17. Membrane association and protein conformation of α-synuclein in intact neurons: Effect of Parkinson's disease linked mutations
18. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation
19. Mutation in the α-synuclein gene identified in families with Parkinson's disease
20. α-Synuclein in Lewy bodies
21. Synphilin-1 is present in Lewy bodies in Parkinson's disease
22. α-Synuclein fibrillogenesis is nucleation-dependent: Implications for the pathogenesis of Parkinson's disease
23. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism